Metabolic syndrome and HCV: Where do we stand in 2010?

Current Hepatitis Reports

Volumn 9, Issue 3, 2010, Pages 133-139

  Lamb, Paul ^a   Harrison, Stephen ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

Hepatitis C; Insulin resistance; Metabolic syndrome; Nonalcoholic fatty liver

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ANTILIPEMIC AGENT; CONNECTIVE TISSUE GROWTH FACTOR; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; INTERLEUKIN 1; INTERLEUKIN 6; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STAT PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR ALPHA;

DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FATTY ACID SYNTHESIS; FATTY LIVER; GENOTYPE; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIVER FIBROSIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 77955980415     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-010-0044-4     Document Type: Review

References (47)

1. Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
2. Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
3. Cabre JJ, Martin F, Costa B, et al.: Metabolic syndrome as a cardiovascular disease risk factor: Patients evaluated in primary care. BMC Public Health 2008, 8:251.
4. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults: executive summary of the third report on the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol inadults (Adult Treatment Panel III). J Am Med Assoc 2001, 285:2486-2497.
5. Negro F, Clement S: Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. J Viral Hepat 2009, 16:681-688.
6. Cesario K, Khandwala F, Edwards K, et al.: Impact of obesity on degree of liver disease and response to therapy in patients with chronic hepatitis C virus infection. J Hepatol 2005, 42(Suppl 2):201-202.
7. Hui JM, Sud A, Farrell GC, et al.: Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003, 123:1695-1704.
8. Kawaguchi T, Yoshida T, Harada M, et al.: Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through upregulation of suppressor of cytokine signaling 3. Am J Pathol 2004, 165:1499-1508.
9. Rubbia-Brandt L, Quadri R, Abid K, et al.: Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000, 33(1):106115.
10. De Gottardi A, Pazienza V, Pugnale P, et al.: Peroxisome proliferator-activated receptor-alpha and gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Aliment Pharmacol Ther 2006, 23:107-114.
11. Bugianesie E, McCullough AJ, Marchesini G: Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005, 42:987-1000.
12. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005, 365:1415-1428.
13. Ervin RB: Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race, and ethnicity, and body mass index: United States, 2003-2006. National health statistics reports: no.13 Hyattsville, MD: National Center for Health Statistics; 2009.
14. Pandya PK, Shah P, Callahan P, et al.: Metabolic syndrome in veterans with chronic HCV infection correlates with NAFLD activity score. Gastroenterology 2006, 130(Suppl 2):A284, abstract s1915.
15. Hanouneh IA, Feldstein AE, Lopez R, et al.: Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2008, 6(5):584-589.
16. Matteoni CA, Younossi ZM, Gramlich T, et al.: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
17. Tsochatzis E, Papatheodoridis GV, Manesis EK, et al.: Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008, 27:80-89. This study demonstrated the link between metabolic syndrome and disease progression in chronic hepatitis C virus.
18. Kang H, Greenson JK, Omo JT, et al.: Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol 2006, 101:2247-2253.
19. Marchesini G, Bugianesi E, Forlani G, et al.: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
20. Gray H, Wreghitt T, Stratton IM, et al.: High prevalence of hepatitis C infection in Afro-Caribbean patients with type 2 diabetes and abnormal liver function tests. Diabet Med 1995, 12:244-249.
21. Papatheodoridis GV, Chrysanthos N, Savvas S, et al.: Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J Viral Hepat 2006, 13:303-310.
22. Mason AL, Lau JY, Hoang N, et al.: Association of diabetes mellitus and chronic hepatis C virus infection. Hepatology 1999, 29:328-333.
23. Younossi ZM, McCullough AJ: Metabolic syndrome, nonalcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int 2009, 29 (Suppl 2):3-12.
24. Kawaguchi T, Ide T, Taniguchi E, et al.: Clearance of HCV improves insulin resistance, B-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007, 102(3):570-576. This study correlated the clearance of HCV and insulin resistance with insulin receptor substrate signaling.
25. Albright E, Bell D: The liver, liver disease, and diabetes ellitus. Endocrinologist 2003, 13:58-66.
26. Strassburg CP, Obermayer-Straub P, Manns MP: Autoimmunity in hepatitis C and D virus infection. J Viral Hepat 1996, 3:49-59.
27. Shintani Y, Fujie H, Moyoshi H, et al.: Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004, 126:840-848.
28. Serfaty L, Capeau J.: Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver International 2009, 29(Suppl 2):13-25.
29. Hotamisligil GS.: The role of TNF-alpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999, 245:621-625.
30. Douglas MW, George J: Molecular mechanisms of insulin resistance in chronic hepatitis C. World J Gastroenterol 2009, 15 (35):4356-4364.
31. Cua IH, Hui JM, Bandara P, et al.: Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 2007, 46:66-73.
32. Alaei M, Negro F: Hepatitis C virus and glucose and lipid metabolism. Diabetes Metab 2008, 34:692-700.
33. Aytug S, Reich D, Sapiro LE, et al.: Impaired IRS-1/P13- kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 2003, 38:1384-1392.
34. Banerjee S, Saito K, Ait-Goughoulte M, et al.: Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance. J Virol 2008, 82:2606-2612.
35. Miyamoto H, Moriishi K, Moriya K, et al.: Involvement of the PA28gamma-dependent pathway in insulin resistance induced by hepatitis C virus core protein. J Virol 2007, 81:1727-1735.
36. Pazienza V, Clement S, Pugnale P, et al.: The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007, 45:1164-1171.
37. Ueki K, Kondo T, Tseng YH, et al.: Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci U S A 2004, 101:10422-10427.
38. Walsh M, Jonsson J, Richardson M, et al.: Non-response to antiviral therapy is associated with obesity and increased expression of hepatic expression of suppressor of cytokine signaling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006, 55:529-535.
39. Bernsmeier C, Duong FH, Christen V, et al.: Virus-induced overexpression of protein phosphatase 2A inhibits insulin signaling in chronic hepatitis C. J Hepatol 2008, 49:429-440.
40. Milner KL, van der Poorten D, Trenell M, et al.: Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology 2010, 138(3):932-941. This study challenges current thinking about the exact site of insulin resistance.
41. Machado MV, Cortez-Pinto H: Insulin resistance and steatosis in chronic hepatitis C. Ann Hepatol 2009, 8(Suppl 1):S67-S75.
42. Del Campo JA, Romero-Gomez M: Steatosis and insulin resistance in hepatitis C: A way out for the virus? World J Gastroenterol 2009, 15(40):5014-5019.
43. Hourioux C, Patient R, Morin A, et al.: The genotype 3- specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut 2007, 56:1302-1308.
44. Rafiq N, Younossi ZM: Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C. Expert Rev. Gastroenterol Hepatol 2008, 2(2):207-215.
45. Harrison SA: Insulin resistance among patients with chronic hepatitis c: etiology and impact on treatment. Clin Gastroenterol Hepatol 2008, 6:864-876.
46. Overbeck K, Genne D, Golay A, et al.: Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. J Hepatol 2008, 49(2):295-298.
47. Romero-Gomez M, Diago M, Andrade RJ, et al.: Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009, 50(6):1702-1708.